Application of genomic principles to pharmacotherapy of cancer

American Journal of Pharmaceutical Education

Volumn 78, Issue 3, 2014, Pages

  Farrell, Christopher L ^a   Pedigo, Nancy G ^a   Messersmith, Amy R ^a  

^a PRESBYTERIAN COLLEGE   (United States)

Author keywords

Active learning; Cancer; Genomics; Oncology; Pharmacogenomics; Pharmacotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; COLORECTAL NEOPLASMS; COMPREHENSION; CURRICULUM; EDUCATION; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; LEARNING; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONCOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROCEDURES; TEACHING; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMPREHENSION; CURRICULUM; DNA MUTATIONAL ANALYSIS; EDUCATION, PHARMACY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; LEARNING; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MUTATION; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; TEACHING;

EID: 84898887956     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/ajpe78355     Document Type: Article

References (42)

1. Accreditation Council for Pharmacy Education. Accreditation standards and guidelines for the professional program in pharmacy leading to the doctor of pharmacy degree. February 2006. https:// www.acpe-accredit.org/pdf/ ACPE_Revised_PharmD_Standards_Adopted_Jan152006.pdf. Accessed October 1, 2013.
2. Turner CJ, Altier R, Fish D, et al. An assessment system for mapping CAPE outcomes in an advanced pharmacy practice experience program. Am J Pharm Educ. 2006;70(3):Article 60.
3. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314 (5797):268-274.
4. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6(5):279-286.
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
6. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94(5):1593-1611.
7. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29(1 Suppl 4):47-50.
8. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-1664.
9. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013;14(8):703-710.
10. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109.
11. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
12. Highlights of prescribing information for Erbitux (cetuximab). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/ 125084s168lbl.pdf. Accessed October 1, 2013
13. Highlights of prescribing information for Vectibix (panitumumab). http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf. Accessed October 1, 2013.
14. Highlights of prescribing information for Zelboraf (vemurafenib). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/ 202429s000lbl.pdf. Accessed October 1, 2013.
15. McCullough KB, Formea CM, Berg KD, et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011;75(3):Article 51.
16. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
17. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263-1284.
18. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867.
19. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-5712.
20. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11 (8):753-762.
21. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924-5930.
22. Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 2012;72(3):779-789.
23. Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PloS One. 2011;6(6):e21632.
24. Trainer DL, Kline T, McCabe FL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer. 15 1988;41(2):287-296.
25. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
26. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010;38(Database issue):D652-657.
27. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006;5(11):2606-2612.
28. Chen TR, Dorotinsky CS, McGuire LJ, Macy ML, Hay RJ. DLD- 1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin. Cancer Genet Cytogenet. 1995;81(2):103-108.
29. Kirkland SC. Dome formation by a human colonic adenocarcinoma cell line (HCA-7). Cancer Res. 1985;45(8):3790-3795.
30. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977;59(1):221-226.
31. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis MG. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes. 2004;18(5):349-352.
32. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trujillo JM. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976;36(2 Pt 1):467-475.
33. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro. 1976;12(3):180-191.
34. Chakrabarty S, Jan Y, Brattain MG, Tobon A, Varani J. Diverse cellular responses elicited from human colon carcinoma cells by transforming growth factor-beta. Cancer Res. 15 1989;49(8):2112-2117.
35. Leibovitz A, Stinson JC, McCombs WB 3rd, McCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976;36(12):4562-4569.
36. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 1981;41(5):1751-1756.
37. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of highresolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn. 2009;11(2):140-147.
38. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103.
39. Brazeau DA, Brazeau GA. A required course in human genomics, pharmacogenomics, and bioinformatics. Am J Pharm Educ. 2006;70(6):Article 125.
40. Latif DA, McKay AB. Pharmacogenetics and pharmacogenomics instruction in colleges and schools of pharmacy in the United States. Am J Pharm Educ. 2005;69(2):Article 23.
41. Zdanowicz MM, Huston SA, Weston G. Pharmacogenomics in the professional pharmacy curriculum: Content, presentation and importance. Int J Pharm Educ. 2006;2(Fall):1-12.
42. National Coalition for Health Professional Education in Genetics. Core competencies for all health professionals. http://www. nchpeg.org/index.php? option5com_content&view5article&id5237&Itemid 584. Accessed June 1, 2013.